Snehal Patel Acquires 5,500 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 5,500 shares of the firm’s stock in a transaction dated Friday, April 4th. The shares were bought at an average cost of $8.73 per share, with a total value of $48,015.00. Following the transaction, the chief executive officer now directly owns 5,558,002 shares of the company’s stock, valued at approximately $48,521,357.46. This represents a 0.10 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Snehal Patel also recently made the following trade(s):

• On Friday, January 10th, Snehal Patel acquired 2,500 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $12.51 per share, with a total value of $31,275.00.
• On Tuesday, January 7th, Snehal Patel bought 1,800 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $13.75 per share, for a total transaction of $24,750.00.

Greenwich LifeSciences Trading Up 8.6 %

GLSI stock opened at $9.59 on Tuesday. The firm has a market cap of $126.06 million, a P/E ratio of -11.99 and a beta of 1.76. Greenwich LifeSciences, Inc. has a 12-month low of $8.06 and a 12-month high of $18.75. The stock’s 50 day simple moving average is $11.65 and its 200 day simple moving average is $12.75.

Institutional Investors Weigh In On Greenwich LifeSciences

Institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN boosted its stake in Greenwich LifeSciences by 54.8% in the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company’s stock valued at $32,000 after acquiring an additional 1,008 shares during the period. Brown Brothers Harriman & Co. acquired a new position in Greenwich LifeSciences during the 4th quarter valued at approximately $45,000. JPMorgan Chase & Co. boosted its position in Greenwich LifeSciences by 172.0% during the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock valued at $79,000 after purchasing an additional 4,465 shares during the period. Bank of America Corp DE grew its stake in Greenwich LifeSciences by 22.3% during the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after buying an additional 1,322 shares during the last quarter. Finally, Barclays PLC lifted its stake in Greenwich LifeSciences by 12.7% in the fourth quarter. Barclays PLC now owns 9,648 shares of the company’s stock valued at $108,000 after buying an additional 1,088 shares during the last quarter. Institutional investors own 4.16% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $38.00 price objective on shares of Greenwich LifeSciences in a report on Tuesday, February 11th.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.